Researchers Identified Protein That Shields Tumors
A study published September 3, 2026, reveals how tumors use an antioxidant protein to evade the immune system.
Updated on Sept. 19, 2026 in Cancer
Live Poll
Do you believe taking antioxidant supplements is generally beneficial for your long-term health?
Researchers at the University of Cambridge and Oregon Health & Science University identified that tumors release the antioxidant protein Peroxiredoxin 1 (PRDX1) to suppress immune attacks. This mechanism prevents T cells from activating against cancer cells, suggesting a potential target for future immunotherapies.
Why it matters
By clearing reactive oxygen species that T cells need to launch an attack, tumors effectively disarm the immune system. Understanding this process explains why some cancers escape detection and suggests that targeting this protein could help reinvigorate the body's immune response.
In a preclinical study using CRISPR to create mouse cancer cells unable to produce PRDX1, researchers observed increased T cell activity and improved responses to immunotherapy. The protein's presence was also confirmed in human cancer cell lines and tumor fluid.
The players
University of Cambridge
A research institution focused on advanced medical science and oncology.
Oregon Health & Science University
A public research university recognized for its contributions to clinical oncology and immunotherapy.
The details
T cells naturally rely on reactive oxygen species (ROS) to trigger their immune function against malignant cells. Tumors secrete PRDX1 into the surrounding microenvironment to scavenge these ROS, thereby neutralizing the signals needed for T cells to initiate an attack. By using CRISPR to disable PRDX1 production, the researchers demonstrated that tumors become more susceptible to immune-based treatments.
Timeline
September 3, 2026: The research findings were published in the journal Science.
Health Landscape
This finding marks a shift in cancer immunotherapy by highlighting how tumors manipulate their local microenvironment to survive. It builds on the long-standing challenge of overcoming treatment resistance that prevents many patients from benefiting from current immune-based therapies.
This preclinical discovery is currently limited to laboratory models and does not change clinical treatment options today. Patients interested in how new immunotherapy targets are developing should discuss the latest evidence and clinical trial eligibility with their oncology team.
The takeaway
Tumors may use antioxidants to hide from the immune system, providing a new target for drug development. As research progresses, maintain a conversation with your physician regarding evidence-based treatments and avoid self-prescribing antioxidant supplements, which have not shown cancer prevention benefits.
Further reading
For more on the latest research in this field, visit our Cancer section.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Do you believe taking antioxidant supplements is generally beneficial for your long-term health?
